- Data from a tertiary hospital suggest that dupilumab (Dupixent) had comparable effectiveness and safety for moderate to severe atopic dermatitis, as in phase 3 randomized clinical trials (RCTs).
Why this matters
- Real-world data are needed to confirm the effectiveness and safety of therapies approved on the basis of phase 3 trials.
- Dupilumab was associated with a 72.4% improvement in Eczema Area and Severity Index (EASI) score at 1 month, and a 76.7% improvement at 3 months (P<.001 for both>
- Dupilumab was also associated with improved itch (P<.001 sleep dermatology life quality index score serum total ige and lactate dehydrogenase p at months.>
- Reductions in EASI score were correlated with LDH at 3 months (P=.003).
- 1 patient (2.3%) discontinued because of adverse effects.
- 18.4% of patients experienced conjunctivitis during 3-month follow-up.
- 43 patients with moderate to severe atopic dermatitis treated with dupilumab were included.
- Funding: None.
- Small patient sample size.
- No comparator group.